Hologic, Inc. (NASDAQ:HOLX) – Analysts at Jefferies Group dropped their Q2 2018 earnings per share estimates for Hologic in a report issued on Wednesday. Jefferies Group analyst R. Denhoy now forecasts that the medical equipment provider will post earnings of $0.56 per share for the quarter, down from their previous estimate of $0.57. Jefferies Group has a “Buy” rating and a $49.00 price target on the stock. Jefferies Group also issued estimates for Hologic’s Q3 2018 earnings at $0.59 EPS, Q4 2018 earnings at $0.59 EPS, FY2018 earnings at $2.28 EPS, FY2019 earnings at $2.59 EPS and FY2020 earnings at $2.96 EPS.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.49 by $0.01. Hologic had a return on equity of 23.18% and a net margin of 25.65%. The business had revenue of $806.10 million for the quarter, compared to analyst estimates of $799.70 million. During the same quarter in the previous year, the firm earned $0.51 earnings per share. The company’s revenue was up 12.4% on a year-over-year basis.

ILLEGAL ACTIVITY NOTICE: “Q2 2018 EPS Estimates for Hologic, Inc. (HOLX) Reduced by Analyst” was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this news story on another site, it was illegally copied and republished in violation of international copyright law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/08/09/q2-2018-eps-estimates-for-hologic-inc-holx-reduced-by-analyst.html.

Several other brokerages have also weighed in on HOLX. Stifel Nicolaus raised their target price on Hologic from $45.00 to $48.00 and gave the stock a “buy” rating in a research report on Thursday, May 11th. Bank of America Corporation restated a “neutral” rating and set a $48.00 price target (up previously from $44.00) on shares of Hologic in a research note on Friday, July 21st. Canaccord Genuity restated a “buy” rating and set a $53.00 price target on shares of Hologic in a research note on Tuesday, May 9th. Piper Jaffray Companies restated a “buy” rating and set a $51.00 price target on shares of Hologic in a research note on Friday, July 14th. Finally, BidaskClub downgraded Hologic from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $48.64.

Shares of Hologic (NASDAQ HOLX) traded down 1.49% during midday trading on Monday, hitting $38.38. The stock had a trading volume of 2,415,975 shares. Hologic has a one year low of $35.15 and a one year high of $46.80. The stock has a market cap of $10.76 billion, a PE ratio of 14.29 and a beta of 0.90. The firm has a 50 day moving average price of $44.73 and a 200 day moving average price of $42.94.

In other Hologic news, Director Lawrence M. Levy sold 2,960 shares of Hologic stock in a transaction that occurred on Wednesday, June 7th. The stock was sold at an average price of $44.54, for a total value of $131,838.40. Following the transaction, the director now directly owns 45,634 shares in the company, valued at approximately $2,032,538.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Elaine Ullian sold 6,902 shares of Hologic stock in a transaction that occurred on Thursday, August 3rd. The shares were sold at an average price of $40.12, for a total value of $276,908.24. Following the completion of the transaction, the director now owns 23,810 shares in the company, valued at $955,257.20. The disclosure for this sale can be found here. Insiders sold a total of 60,627 shares of company stock worth $2,632,911 over the last quarter. Company insiders own 0.79% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. TrimTabs Asset Management LLC increased its stake in Hologic by 88.8% in the first quarter. TrimTabs Asset Management LLC now owns 2,993 shares of the medical equipment provider’s stock worth $127,000 after buying an additional 1,408 shares in the last quarter. Advisor Partners LLC acquired a new stake in Hologic during the first quarter worth $201,000. Miles Capital Inc. acquired a new stake in Hologic during the first quarter worth $206,000. Beck Mack & Oliver LLC acquired a new stake in Hologic during the second quarter worth $209,000. Finally, Stratos Wealth Partners LTD. acquired a new stake in Hologic during the first quarter worth $210,000. Institutional investors own 94.46% of the company’s stock.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Earnings History and Estimates for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.